This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
CONFIRM
Our Technology Platform

Acepodia has designed enhanced cell therapy approaches that are differentiated with bolstered potency for enhanced tumor-killing. The company's next-generation therapies are based on proprietary immune cells combined with both novel and well-established targeting mechanisms through Antibody-Cell Conjugation (ACC) and Chimeric Antigen Receptor (CAR) technology.

  • oNK Cells

    oNK Cells

    oNK cells are a unique off-the-shelf natural killer cell line, with potent anticancer activity, ideally suited for application of tumor-targeting machinery, such as through ACC or CAR technology.

    oNK Cells
  • ACC

    ACC

    ACC technology is a new approach to cell therapy development that attaches tumor-targeting antibodies directly to the surface of immune cells to enhance and direct their anticancer activity. Acepodia is applying this technology to its oNK cells and gamma delta T cells.

    ACC
  • CAR

    CAR

    CARs are receptors designed to recognize specific tumor antigens and can be genetically introduced into immune cells, like NK cells or T cells, to allow them to engage and eradicate cancer cells. Acepodia is applying this technology to its oNK cells and gamma delta T cells test test test test test test test test.

    CAR
  • γδ T cells

    γδ T cells

    Gamma delta T cells are an off-the-shelf cell line that can directly target cancer cells as well as recruit the immune system to elicit a robust anticancer response.

    γδ T cells